SQZ Biotech Presents Preclinical Data on its mRNA-based enhanced APCs & the Potential of the SQZ APC Platform in KRAS Driven ...
10 4월 2021 - 9:30PM
Business Wire
SQZ enhanced APCs (eAPCs) demonstrated ability
to meaningfully increase CD8 T cell response through incorporation
of costimulatory molecules and cytokine signaling
mRNA cargo in eAPCs enabled presentation of
broader antigen repertoire, potentially expanding addressable
patient populations
SQZ-APC-KRAS showed preclinical
proof-of-concept for potential applicability to multiple KRAS
mutations, highlighting the opportunity for expansion into
additional tumor types
SQZ Biotechnologies (NYSE: SQZ), a cell therapy company
developing novel treatments for multiple therapeutic areas, today
shared preclinical data from its next generation SQZ™ APCs,
enhanced APCs or eAPCs, and the potentially broader applicability
of the platform at the American Association for Cancer Research
(AACR) 2021 Annual Meeting.
“One of the advantages of the Cell Squeeze® technology is the
ability to simultaneously engineer multiple functions in cells, the
underpinning of our SQZ eAPC program. With this next generation
program, we are aiming to achieve the benefits of combination
therapies that can drive powerful immune responses within a single
multiplexed cell therapy,” said Howard Bernstein, MD, PhD, chief
scientific officer of SQZ. “Our vision is to incorporate additional
functionality and new antigens to the foundation we are
establishing with our lead SQZ APC program. The eAPC and KRAS data
presented at AACR provide preclinical examples of how we could
potentially extend our impact across indications and help more
patients.”
SQZ eAPCs build on the power of the SQZ APC platform, which is
focused on producing robust and specific CD8 T cell activation
through efficient MHC-I antigen presentation. By delivering
multiple mRNA into cells in a single squeeze, SQZ eAPCs are
designed to further enhance T cell stimulation and boost
immune-signaling that would otherwise require combinations with
additional immune-oncology agents. In addition, the mRNA-based
cargo facilitates presentation of a broader range of tumor
epitopes, which could expand the addressable HPV+ patient
population. The eAPC platform offers the opportunity for
application across oncology and infectious diseases.
Highlights from the SQZ eAPC preclinical data shared at AACR
(Posters 1525 and 2626) include:
- Enhancement of the quality and quantity of CD8 T cell
activation by SQZ eAPCs through incorporation of CD86, membrane
bound IL-2 (mbIL-2), and membrane bound IL-12 (mbIL-12), leveraging
multiplexed delivery of mRNAs encoding each component
- mbIL-2 and mbIL-12 mRNA delivery via Cell Squeeze® led to
surface expression of the cytokines in all measured human PBMC
subsets (B cells, T cells, NK cells, and monocytes) and resulted in
functional IL-2 and IL-12 signaling
- CD86, mbIL-2, and mbIL-12 mRNA delivered alone or in
combination increased antigen-specific CD8 T cell responses as much
as ten-fold
- Multiplexing CMVpp65 and influenza M1 mRNA antigens with signal
2/3 mRNAs enhanced the potency of SQZ APCs - inducing stronger
antigen-specific CD8 T cell responses for infectious disease
- Co-squeezing E6 and E7 mRNAs drove antigen-specific CD8 T cell
activation regardless of HLA haplotype, which could significantly
broaden the addressable HPV+ patient population and potentially
eliminate the need for HLA screening
- Cell Squeeze® mRNA delivery stimulated memory CD8 T cells
across various antigens and HLA haplotypes
SQZ is leveraging the cargo flexibility of its Cell Squeeze®
technology to pursue additional tumor targets. SQZ APCs have
demonstrated the ability to elicit specific KRAS G12D and G12V CD8+
T cell responses in both animal models and in human cells.
Highlights from the SQZ-APC-KRAS preclinical data shared at AACR
(Poster 1524) include:
- SQZ APCs engineered with KRas G12D and G12V peptides, both
alone and multiplexed, generated specific and robust CD8 T cell
responses against the target mutations
- KRAS G12D and G12V make up over half of all KRAS mutations,
with approximately 100,000 patients per year having KRAS G12D or
G12V mutated cancers in the United States
About SQZ Biotechnologies
SQZ Biotechnologies is a clinical-stage biotechnology company
developing transformative cell therapies for patients with cancer,
infectious diseases, and other serious conditions. Using its
proprietary technology, SQZ Biotechnologies offers the unique
ability to deliver multiple materials into many patient cell types
to engineer what we believe can be an unprecedented range of
potential therapeutics for a variety of diseases. SQZ
Biotechnologies has the potential to create well-tolerated cell
therapies that can provide therapeutic benefit for patients and to
improve the patient experience over existing cell therapy
approaches. With accelerated production timelines under 24 hours
and the opportunity to eliminate preconditioning and lengthy
hospital stays, our goal is to use the SQZ approach to establish a
new paradigm for cell therapies. Our first therapeutic applications
aim to leverage the potential to generate target-specific immune
responses, both in activation for the treatment of solid tumors and
immune tolerance for the treatment of unwanted immune reactions and
autoimmune diseases. For more information, please visit
www.sqzbiotech.com.
Forward Looking Statement
This press release contains forward-looking statements within
the meaning of the Private Securities Litigation Reform Act of
1995. All statements contained that do not relate to matters of
historical fact should be considered forward-looking statements,
including without limitation statements relating to scientific
events and presentations, our product candidates, preclinical
activities, development plans, application across indications,
clinical efficacy and therapeutic impact. These forward-looking
statements are based on management's current expectations. Actual
results could differ from those projected in any forward-looking
statements due to several risk factors. Such factors include, among
others, risks and uncertainties related to our limited operating
history; our significant losses incurred since inception and
expectation to incur significant additional losses for the
foreseeable future; the development of our initial product
candidates, upon which our business is highly dependent; the impact
of the COVID-19 pandemic on our operations and clinical activities;
our need for additional funding and our cash runway; the lengthy,
expensive, and uncertain process of clinical drug development,
including uncertain outcomes of clinical trials and potential
delays in regulatory approval; our ability to maintain our
relationships with our third party vendors; and protection of our
proprietary technology, intellectual property portfolio and the
confidentiality of our trade secrets. These and other important
factors discussed under the caption "Risk Factors" in our Annual
Report on Form 10-K and other filings with the U.S. Securities and
Exchange Commission could cause actual results to differ materially
from those indicated by the forward-looking statements. Any
forward-looking statements represent management's estimates as of
this date and SQZ undertakes no duty to update these
forward-looking statements, whether as a result of new information,
the occurrence of current events, or otherwise, unless required by
law.
Certain information contained in this press release relates to
or is based on studies, publications, surveys and other data
obtained from third-party sources and our own internal estimates
and research. While we believe these third-party sources to be
reliable as of the date of this press release, we have not
independently verified, and we make no representation as to the
adequacy, fairness, accuracy or completeness of any information
obtained from third-party sources.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20210410005002/en/
SQZ Biotechnologies IR Contact: Rebecca Cohen Corporate
and Investor Relations rebecca.cohen@sqzbiotech.com 617-758-8672
ext. 728
Media Contact: Kate Contreras kcontreras@w2ogroup.com
617-229-5960
SQZ Biotechnologies (NYSE:SQZ)
과거 데이터 주식 차트
부터 6월(6) 2024 으로 7월(7) 2024
SQZ Biotechnologies (NYSE:SQZ)
과거 데이터 주식 차트
부터 7월(7) 2023 으로 7월(7) 2024